[HTML] aacrjournals.org

[HTML][HTML] SHP2 inhibition sensitizes diverse oncogene-addicted solid tumors to re-treatment with targeted therapy

A Drilon, MR Sharma, ML Johnson, TA Yap, S Gadgeel… - Cancer discovery, 2023 - AACR
Rationally targeted therapies have transformed cancer treatment, but many patients develop
resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an …
被引用次数：26 相关文章

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

A Drilon, MR Sharma, ML Johnson… - Cancer …, 2023 - pubmed.ncbi.nlm.nih.gov
Rationally targeted therapies have transformed cancer treatment, but many patients develop
resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an …

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.

A Drilon, MR Sharma, ML Johnson, TA Yap… - Cancer …, 2023 - europepmc.org
Rationally targeted therapies have transformed cancer treatment, but many patients develop
resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an …

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

A Drilon, MR Sharma, ML Johnson… - Cancer …, 2023 - scholarlycommons.henryford.com
UNLABELLED: Rationally targeted therapies have transformed cancer treatment, but many
patients develop resistance through bypass signaling pathway activation. PF-07284892 …
[PDF] aacrjournals.org

[PDF][PDF] SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

A Drilon, MR Sharma, ML Johnson, TA Yap, S Gadgeel… - Cancer Discovery, 2023 - AACR
Rationally targeted therapies have transformed cancer treatment, but many patients develop
resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an …

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

A Drilon, MR Sharma, ML Johnson… - Cancer …, 2023 - mdanderson.elsevierpure.com
Rationally targeted therapies have transformed cancer treatment, but many patients develop
resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an …
[PDF] semanticscholar.org

[PDF][PDF] SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

A Drilon, MR Sharma, ML Johnson, TA Yap, S Gadgeel… - 2023 - pdfs.semanticscholar.org
Rationally targeted therapies have transformed cancer treatment, but many patients develop
resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an …
[HTML] nih.gov

[HTML][HTML] SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

A Drilon, MR Sharma, ML Johnson, TA Yap… - Cancer …, 2023 - ncbi.nlm.nih.gov
Rationally targeted therapies have transformed cancer treatment, but many patients develop
resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an …
[HTML] nih.gov

[HTML][HTML] SHP2 inhibition sensitizes diverse oncogene-addicted solid tumors to re-treatment with targeted therapy

A Drilon, MR Sharma, ML Johnson, TA Yap… - Cancer …, 2023 - ncbi.nlm.nih.gov
Rationally targeted therapies have transformed cancer treatment, but many patients develop
resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an …